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Allogeneic hematopoietic cell transplantation in
acute myeloid leukemia with normal karyotype and
isolated Nucleophosmin-1 (NPM1) mutation: 
outcome strongly correlates with disease status
Treatment of acute myeloid leukemia (AML) is gener-
ally dictated by the patient’s age and  performance status
and the biological, genetic, and molecular characteristics
of the disease.1 Specific cytogenetic alterations divide
AML classification into three risk-based categories: favor-
able, intermediate and unfavorable.2,3 Patients with nor-
mal karyotype belong to the intermediate-risk category,
and their prognosis is further determined by specific
genetic alterations, particularly Nucleophosmin-1 (NPM1)
mutation and FLT-3 internal tandem duplication (ITD).4-6 
NPM1 is an essential gene that encodes a nucleolar
shuttling protein. It is the most frequently mutated gene
in AML, accounting for more than one third of all AML
cases.7,8 In patients with normal diploid karyotype, NPM1
mutation, when present alone, is associated with a lower
risk of relapse, and confers a major survival advantage.9
However, the presence of both NPM1 mutation and
FLT3-ITD results in a poor prognosis. Therefore, patients
with unmutated NPM1 or patients with both NPM1
mutation and FLT3-ITD are generally referred for an allo-
geneic hematopoietic cell transplant (allo-HCT) in first
complete remission (CR1). Conversely, patients with nor-
mal karyotype and NPM1 mutation without FLT3-ITD
belong to the European LeukemiaNet (ELN) favorable-
risk group and, accordingly, are referred to transplant
only at the time of relapse. However, little is known
about post-transplant outcomes in this particular setting
and the predictive factors for disease-free survival.
Furthermore, recent data based on the donor versus no-
donor approach indicates a beneficial effect of allo-HCT
on leukemia-free survival (LFS) but not overall survival
(OS) for NPM1+FLT3- AML patients.10-12 
To explore the prognosis of patients allografted for
AML with normal diploid karyotype and mutated NPM1
without FLT3-ITD, we performed a retrospective multi-
center analysis. Data were provided and approved for
this study by the Acute Leukemia Working Party (ALWP)
of the EBMT group registry. The latter is a voluntary
working group of more than 500 transplant centers that
are required to report all consecutive stem cell transplan-
tations and follow-ups once a year. The participating cen-
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Table 1. Patient, disease and treatment characteristics.
Variables N (%) CR1 (n=69) CR2 (n=64) Active (n=23) P (global) P (CR1 vs. CR2)
Median age (range), years 54.3 (19.5-71) 52y (24-67) 56 (19.5-71) 53 (33-66) 0.24 0.16
Recipient male gender 73 (46.8) 30 (43.5%) 34 (53.1%) 9 (39.1%) 0.39 0.27
Donor male gender 97 (63%) 43 (63.2%) 36 (57.1%) 18 (78.3%) 0.20 0.48
Female donormale recipient 21 (13.6%) 8 (11.8%) 12 (19%) 1 (4.3%) 0.18 0.25
Donor source, 90 (57.7%)
MUD 31 (44.9%) 45 (70.3%) 14 (60.9%) 0.012 0.003
Recipient CMV seropositive serology 101 (65.2%) 45 (66.2%) 44 (68.8%) 12 (52.2%) 0.35 0.75
Donor CMV seropositive serology 62 (40.3%) 33 (48.5%) 23 (35.9%) 6 (27.3%) 0.14 0.14
CMV donor/recipient 
Donor+/Rec+ 48 (31.4%) 19 (28.4%) 13 (20.3%) 7 (31.8%)
Donor +/Rec- 14 (9.2%) 4 (6%) 7 (10.9%) 3 (13.6%)
Donor-/Rec+ 52 (34%) 15 (22.4%) 28 (43.8%) 9 (40.9%)
Donor-/Rec- 39 (25.5%) 29 (43.3%) 16 (25%) 3 (13.6%) 0.04 0.02
missing 3 2 0 1
Cell source
PBSC 126 (80.8%) 51 (73.9%) 52 (81.3%) 23 (100) 0.023 0.31
BM 30 (19.2%) 18 (26.1%) 12 (18.8%)
Molecular remission at transplant for CR1 or CR2
Yes 22 (62.9%) 16 (55.2%) 0.53
No 13 (37.1%) 13 (44.8%)
missing 34 35
Preparative regimen
RIC 85 (54.5%) 37 (53.4%) 36 (56.3%) 12 (52.2%)
MAC 71 (45.5%) 32 (46.4%) 28 (43.8%) 11 (47.8%) 0.93 0.76
ATG use
Yes 84 (53.8%) 33 (47.8%) 37 (57.8%) 14 (60.9%) 0.39 0.25
GVHD prophylaxis
CsA+MTX 77 (49.4%) 35 (50.7%) 36 (57.1%) 6 (26.1%)
CsA+MMF 41 (26.3%) 13 (18.8%) 16 (25;'%) 12 (52.2%)
CsA alone 28 (17.9%) 15 (21.7%) 10 (15.ç%) 3 (13%)
other 9 (5.8%) 6 (8.7%) 1 (1.6%) 2 (8.7%) 0.02 0.20
missing 1 0 1 0 
CR1: first complete remission; CR2: second complete remission; MUD: matched unrelated donors, CMV: cytomegalovirus, PBSC: G-CSF mobilized peripheral blood stem cells;
BM: unstimulated bone marrow; RIC: reduced-intensity conditioning; MAC: myeloablative conditioning; ATG: antithymocyte globulin; CsA: cyclosporine A, MTX: methotrexate;
MMF: mycophenolate mofetil.
ters are listed in the Online Supplementary TableS1. Audits
are routinely performed to determine the accuracy of the
data. Since 1990, patients have provided informed con-
sent authorizing the use of their personal information for
research purposes. Eligibility criteria for this analysis
included adult patients (age >18 years) with AML, trans-
planted between 2006 and 2012, from an HLA-matched
related (MRD) or matched unrelated (MUD) donor with
bone marrow (BM) or G-CSF-mobilized peripheral blood
stem cells (PBSCs). 
Endpoints included LFS, cumulative incidence of
relapse (CIR), NRM, OS and acute and chronic GVHD.
The probabilities of OS and LFS were calculated by using
the Kaplan-Meier estimator. The probabilities of acute
and chronic GVHD, NRM, and relapse were calculated
by using the cumulative incidence estimator to accom-
modate competing risks. For NRM, relapse was the com-
peting risk, and for relapse, the competing risk was NRM.
For acute and chronic GVHD, death without the event
was the competing risk. For all prognostic analyses, con-
tinuous variables were categorised and the median was
used as a cut-off point. Univariate comparisons were
done using the log-rank test for LFS and OS, and Gray’s
test was used for cumulative incidences. Chronic GVHD
was analyzed as a time-dependent variable. A Cox pro-
portional hazards model was used for multivariate regres-
sion. Factors known to influence the outcome associated
with a P value less than 0.10 with any endpoint by uni-
variate analysis were included in the model. Results are
expressed as hazard ratio (HR) with 95% confidence
interval (CI). All tests were two-sided. Statistical analyses
were performed with SPSS 19 (SPSS Inc./IBM, Armonk,
NY, USA) and R 3.0.1 (R Development Core Team,
Vienna, Austria) software packages.
In this study, we evaluated the post-transplant out-
comes of 156 patients (females=83, 53%; males=73,
47%), with a median age of 54.3 (19.5-71) years and nor-
mal diploid karyotype and mutated NPM1 without 
FLT3-ITD, who underwent an allo-HCT between 2006
and 2012. The median follow-up from time of allograft-
ing was 32 (2-86) months. At transplantation, 69 patients
(44%) were in CR1, 64 (41%) in CR2 and 23 (15%) had
advanced/active disease. The median time from initial
diagnosis to transplantation was 161 (89-483) days in
patients transplanted in CR1, 618 (189-1333) days in CR2
and 315 (189-896) days in advanced/active disease. The
median time from diagnosis to CR1 was 39 (16-176) days
in patients transplanted in CR1 and 41 (14-169) days in
patients transplanted in CR2. The graft source was limit-
ed to matched related (MRD) (N=66, 42%) or matched
unrelated (MUD) donors (N=90, 58%), including 21 male
patients (14%) allografted from female donors. The cell
source consisted of BM (N=30, 19%), G–CSF mobilized
PBSC (N=125, 80%), or both (N=1). A reduced intensity
conditioning (RIC) was used in 85 patients (54%), where-
as 71 (46%) received a myeloablative conditioning
(MAC). Patients’, donors’, and disease characteristics are
summarized in Table 1. 
Thirty patients (19%) developed acute GVHD grade II-
IV. Patients allografted from MUD had a higher 100-day
cumulative incidence of acute GVHD above grade II
[MUD=28% (95%CI=19-39%)] than MRD [MRD=12%
(95%CI=5-22%), P=0.02]. Patients older than the median
age had a higher 2-year cumulative incidence of NRM
[20% (95%CI=11-31%) vs. 7% [95%CI=2-14%],
P=0.03]. Overall, the cumulative incidence of cGVHD at
2 years was 37%. When cGVHD was analyzed as a time-
dependent variable, it had no significant effect on CIR
[HR=0.78 (95%CI=0.31-1.97), P=0.59], NRM [HR=3.23
(95%CI=0.83-12.56), P=0.09], LFS [HR=1.21
(95%CI=0.58-2.55), P=0.61] or OS [HR=1.24
(95%CI=0.58-2.64), P=0.58].
In univariate analysis, the presence of advanced/active
disease at the time of allografting was associated with a
higher 2-year CIR [advanced disease=48% (95%CI=26-
67%), CR1=14% (95%CI=7-23%), CR2=37%
(95%CI=23-51%), P=0.0009] (Figure 1A), an inferior 
2-year LFS [advanced disease =30% (95%CI=11-49%),
CR1=75% (95%CI=64-86%), CR2=51% (95%CI=36-
65%), P<0.0001] (Figure 1B) and an inferior 2-year OS
[advanced disease=39% (95%CI=19-59%), CR1=81%
(95%CI=72-91%), CR2=67% (95%CI=54-80%),
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Table 2. Multivariable analysis.
Variables Comparators CIR LFS OS NRM Chronic GVHD
HR[95%CI] HR[95%CI] HR[95%CI] HR[95%CI] HR[95%CI]
P P P P P
Age <median vs. 0.78 [0.40-1.52] 1.07 [0.61-1.88] 1.24 [0.67-2.27] 2.20 [0.77-6.26] 1.30 [0.70-2.41]
>median P=0.46 P=0.80 P=0.50 P=0.14 P=0.40
Year of allografting >2010 vs. ≤2010 0.53 [0.22-1.29] 0.42 [0.19-0.93] 0.45 [0.18-1.13] 0.15 [0.02-1.20] 0.93 [0.47-1.80]
P=0.16 P=0.03 P=0.09 P=0.07 P=0.82
Disease status at transplantation CR2 vs. CR1 3.65 [1.58-8.42] 2.53 [1.33-4.82] 2.30 [1.13-4.67] 1.46 [0.50-4.25] 1.15 [0.61-2.17]
P=0.02 P=0.005 P=0.02 P=0.49 P=0.66
Adv vs.CR1 5.73 [2.26-14.51] 3.94 [1.89-8.19] 3.90 [1.80-8.44] 2.29 [0.67-7.78] 0.81 [0.29-2.27]
P=0.0002 P=0.0002 P=0.001 P=0.19 P=0.69
Donor source MUD vs. MRD 1.68 [0.84-3.39] 1.33 [0.77-2.30] 1.71 [0.91-3.21] 0.86 [0.34-2.18] 0.55 [0.31-0.96]
P=0.14 P=0.31 P=0.09 P=0.75 P=0.03
Recipient CMV serology Pos vs. neg 0.64 [0.33-1.24] 0.95 [0.55-1.66] 1.13 [0.61-2.09] 2.85 [0.80-10.13] 0.84 [0.47-1.50]
P=0.19 P=0.86 P=0.70 P=0.10 P=0.55
Regimen intensity RIC vs. MAC 1.50 [0.77-2.89] 1.26 [0.73-2.15] 1.31 [0.73-2.35] 0.84 [0.33-2.13] 0.95 [0.53-1.69]
P=0.23 P=0.41 P=0.37 P=0.71 P=0.86
CIR: cumulative incidence of relapse; LFS: leukemia-free survival; OS: overall survival; NRM: non-relapse mortality; CR1: first complete remission; CR2: second complete remis-
sion; Adv: advanced or active disease; MUD: matched unrelated donor; MRD: matched related donor; Pos: CMV seropositive; neg: CMV seronegative; RIC: reduced intensity con-
ditioning; MAC: myeloablative conditioning. *Bold denotes statistically significant.
P<0.0001] (Figure 1C). Patients older than 54.3 years had
an inferior 2-year OS [61% (95%CI=49-72%) vs. 78%
(95%CI=68-88%), P=0.02]. The use of in vivo T-cell
depletion has no impact on CIR, OS, LFS and NRM. In
multivariable analysis, using a Cox proportional-hazards
model, advanced disease or CR2 at time of transplant
resulted in a higher 2-year CIR and an inferior 2-year LFS
and OS (Table 2).
In a previous retrospective “donor” versus “no-donor”
analysis of 135 AML patients with a normal karyotype
and NPM1 mutation without FLT3-ITD, Schlenk et al.
reported no difference in relapse-free survival between
the two groups, suggesting no beneficial effect of allo-
HCT in these patients.10 Conversely, using a similar strat-
egy in a small group of FLT3- NPM1+ patients, Rollig et
al. recently reported a better outcome in the donor group
(N=43) in terms of 3-year relapse-free survival (83% 
versus 53%; P=0.004) but not in 3-year OS (81% versus
75%; P=0.3).12 Currently, AML patients with normal
karyotype and NPM1mutation without FLT3-ITD belong
to the ELN favorable-risk group and, accordingly, are
referred for allo-HCT upon relapse. Our results indicate a
3-year LFS close to 40% for CR2 patients, not different
from that of advanced/active disease. Conversely, the 3-
year LFS in CR1 patients is close to 75%, and quite simi-
lar to the 83% reported by Rollig et al.12 The good out-
come of allo-HCT in CR1 in contrast to that in CR2 and
the recent reduction in NRM, together with the relatively
high rate of relapse with only consolidation chemothera-
py in CR1, may suggest revisiting the role of allogeneic
transplant in some of the young AML patients with nor-
mal karyotype and NPM1 mutation, even without FLT3-
ITD, in CR1,12 for example in those patients who are slow
in achieving remission or have high MRD.
One of the important limitations of our retrospective
registry study is the risk of selection bias. Ideally, this
question ought to be answered through a prospective
randomized trial comparing allo-HCT against consolida-
tion chemotherapy in AML patients with normal diploid
karyotype, NPM1 mutation, no FLT3-ITD, and with an
available matched donor. This would, however, require
large international cooperation to achieve the required
sample size.
In conclusion, AML disease status at allografting
remains the most important predictor of post-allogeneic
HCT outcomes despite expression of mutated NPM1.
Survival outcomes are better when patients are trans-
planted in CR1 versus CR2 or advanced/active disease.
Although judged to be good-risk patients and not consid-
ered for allogeneic HCT, CR1 patients with NPM1+
FLT3- are still faced with significant risk of relapse.
Delaying transplant to CR2 leads to around 50% survival.
The impact of other molecular abnormalities in conjunc-
tion with NPM1 is yet to be established. 
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Figure 1. (A) Two-year cumulative incidence of relapse. (B) Two-year leukemia-
free survival. (C). Two-year overall survival.
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